Skip to main content
. 2018 Sep 27;9(12):1648–1655. doi: 10.1111/1759-7714.12875

Figure 2.

Figure 2

Forest plot of treatment to subgroup analysis. (a) Number of bevacizumab treatment cycles: ≥ 5 versus 1–4 cycles. (b) First‐line versus second or later lines of bevacizumab. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NSCLC, non‐small cell lung cancer.